Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis

References

• KahrilasPJShaheenNJVaeziMFAmerican Gastroenterological Association InstitiuteClinical Practice and Quality Management CommitteeAmerican Gastroenterological Association Institute technical review on the management of gastroesophageal reflux diseaseGastroenterology200813541392141318801365
   PubMed Web of Science ®Google Scholar
• GillenDMcCollKELProblems related to acid rebound and tachyphylaxisBest Pract Res Clin Gastro2001153487495
   Web of Science ®Google Scholar
• MetzDCFerronGMPauJProton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human studyJ Clin Pharmacol200242551251912017345
   PubMed Web of Science ®Google Scholar
• SachsGProton pump inhibitors and acid-related diseasesPharmacotherapy199717122379017763
   PubMed Web of Science ®Google Scholar
• SachsGShinJMBrivingCWallmarkBHerseySThe pharmacology of the gastric acid pump: the H+, K+ ATPaseAnnu Rev Pharmacol Toxicol1995352773057598495
   PubMed Web of Science ®Google Scholar
• KatzPOScheimanJMBarkunANReview article: acid-related disease – what are the unmet clinical needs?Aliment Pharmacol Ther200623Suppl 292216700899
   PubMed Web of Science ®Google Scholar
• FennertyMBJohansenJFHwangCSostekMEfficacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitisAliment Pharmacol Ther200521445546315709997
   PubMed Web of Science ®Google Scholar
• LauritsenKDevièreJBigardMAEsomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study resultsAliment Pharmacol Ther200317333334112562445
   PubMed Web of Science ®Google Scholar
• KovacsTOFrestonJWHaberMMAtkinsonSHuntBPeuraDALong-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazoleDig Dis Sci200977 [Epub ahead of print]
   Web of Science ®Google Scholar
• DonnellanCSharmaNPrestonCMoayyediPMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux diseaseCochrane Database Syst Rev20052CD00324515846653
   PubMed Web of Science ®Google Scholar
• InadomiJMMcIntyreLBernardLFendrickAMStep-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIsAm J Gastroenterol20039891940194414499769
   PubMed Web of Science ®Google Scholar
• GosselinALuoRLohouesHThe impact of proton pump inhibitor compliance on health-care utilization and costs in patients with gastroesophageal reflux diseaseValue Health2009121343919895371
   PubMed Web of Science ®Google Scholar
• Van SoestEMSiersemaPDDielemanJPSturkenboomMCKuipersEJPersistence and adherence to proton pump inhibitors in daily clinical practiceAliment Pharmacol Ther200624237738516842465
   PubMed Web of Science ®Google Scholar
• GunaratnamNTJessupTPInadomiJLascewskiDPSub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophgeal reflux diseaseAliment Pharmacol Ther200623101473147716669962
   PubMed Web of Science ®Google Scholar
• BarrisonAFJarboeLAWeinbergBMNimmagaddaKSullivanLMWolfeMMPatterns of proton pump inhibitor use in clinical practiceAm J Med2001111646947311690573
   PubMed Web of Science ®Google Scholar
• KatsukiHYagiHArimoriKDetermination of R(+)- and S(−)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humansPharm Res19961346116158710755
   PubMed Web of Science ®Google Scholar
• Kapidex® [prescribing information]Takeda Pharmaceutical, North AmericaDeerfield, IL2009
   Google Scholar
• KatsukiHHamadaANakamuraCArimoriKNakanoMRole of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomesEur J Clin Pharmacol2001571070971511829200
   PubMed Web of Science ®Google Scholar
• VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trialsCurr Med Res Opin200925362763819232037
   PubMed Web of Science ®Google Scholar
• MayerMDVakilyMWittGMulfordDJThe pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis [abstract]Gastroenterology2008 1344Suppl 1A176
   Google Scholar
• MetzMCVakilyMDixitTMulfordDReview article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapyAliment Pharmacol Ther200929992893719298580
   PubMed Web of Science ®Google Scholar
• ZhangWWuJAtkinsonSPharmacokinetic (PK), pharmacodynamic (PD), and safety evaulation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole (Lan) in healthy subjects. [abstract]Gastroenterology20071324 Suppl 2487
   Web of Science ®Google Scholar
• LeeRDVakilyMMulfordDWuJAtkinsonSNClinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor – evidence for dosing flexibilityAliment Pharmacol Ther200929882483319243357
   PubMed Web of Science ®Google Scholar
• LeeRDMulfordDWuJAtkinsonSNThe effect of time-of-day dosing of TAK-390MR on the pharmacokinetics and pharmacodynamics of TAK-390: evidence for dosing flexibility with this dual delayed release proton pump inhibitor [abstract]Gastroenterology20091365 Suppl 1A-440
   Web of Science ®Google Scholar
• PehlivanovNDOlyaeeMSarosiekIMcCallumRWComparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind cross-over studyAliment Pharmacol Ther200318988389014616152
   PubMed Web of Science ®Google Scholar
• HongoMOharaSHirasawaYAbeSAsakiSToyotaTEffect of lansoprazole on intragastric pH. Comparison between morning and evening dosingDig Dis Sci19923768828901534047
   PubMed Web of Science ®Google Scholar
• FraserAGSawyerrAMHudsonMSmithMSPounderREMorning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjectsAliment Pharmacol Ther19961045235278853755
   PubMed Web of Science ®Google Scholar
• CzerniakRVakilyMWuJTAK-390MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled over applesauce. [abstract]Am J Gastroenterol2008103Suppl SS4S5
   Web of Science ®Google Scholar
• VakilyMLeeRDWuJGunawardhanaLMulfordDDrug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studiesClin Drug Invest20092913550
   Web of Science ®Google Scholar
• LeeRDWuJVakilyMMulfordDEffect of hepatic impairment on the pharmacokinetics of TAK-390MR (modified release) [abstract]Clin Pharmacol Ther200883Suppl 1S95
   Google Scholar
• VakilyMZhangWWuJMulfordDEffect of age and gender on the pharmacokinetics of a single oral dose of TAK-390MR (modified release) [abstract]Clin Pharmacol Ther200883Suppl 1S96
   Google Scholar
• ZhangWWuJVakilyMPharmacokinetics of TAK-390MR (modified-release) 30, 60, and 90 mg in subjects with symptomatic, non-erosive gastroesophageal reflux disease (GERD) [abstract]Clin Pharmacol Ther200883Suppl 1S96
   Google Scholar
• SharmaPShaheenNJPerezMCClinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studiesAliment Pharmacol Ther200929773174119183157
   PubMed Web of Science ®Google Scholar
• MetzDCHowdenCWPerezMCLarsenLO’NeilJAtkinsonSNClinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitisAliment Pharmacol Ther200929774275419210298
   PubMed Web of Science ®Google Scholar
• HowdenCLarsenLPalmerRPerezMCPlacebo-controlled trial of 2 doses of TAK-390MR, a PPI with novel dual delayed release technology, as maintenance treatment for patients with healed erosive esophagitis (EE)Aliment Pharmacol Ther200930989590719681809
   PubMed Web of Science ®Google Scholar
• FassRCheyWDZakkoSFClinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux diseaseAliment Pharmacol Ther200929121261127219392864
   PubMed Web of Science ®Google Scholar
• ZhangWWuJAtkinsonSNEffects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjectsJ Clin Pharmacol200949444445419318694
   PubMed Web of Science ®Google Scholar
• VakilyMWuJAtkinsonSEffect of single oral doses (90 and 300 mg) of TAK-390MR on QT intervals. [abstract]Clin Pharmacol Ther200781Suppl 1S26
   Google Scholar